JM
Jarrod Meehleib
Territory Manager at Kedrion Biopharma
View Jarrod's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Territory Manager
Oct 2021 - Present · 3 years and 2 months
Market Manager
Feb 2021 - Nov 2021 · 9 months
Esperion Therapeutics
Territory Manager
Mar 2020 - Feb 2021 · 11 months
Company Details
1001-5000 Employees
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.
Year Founded
2001
Social Media
Linkedin
Industry
Pharmaceutical Manufacturing, Chemicals and pharmaceuticals (wholesale), General traders, department and retail stores, Retail & Traders
HQ Location
--
Keywords
Plasma-derived medicinal products and Plasma collection
Discover More About Cleveland Clinic

Find verified contacts of Jarrod Meehleib in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.